Phanes Therapeutics Raises $40 Million for mAb and Bi-specific Portfolio
June 02, 2021 at 06:40 AM EDT
Phanes Therapeutics, a San Diego-Shanghai immunoncology company, completed a $40 million Series B financing. The company is developing a pipeline of seven mAb and bi-specific pre-clinical candidates that it discovered using its two technology platforms. The B round was led by Sequoia Capital China. Phanes said it would use the proceeds to advance several pre-clinical programs into the clinic, expand its research and clinical teams, and advance new research projects. More details.... Share this with colleagues: // //